Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

Langzeitanalyse von Parametern der Lebensqualität sowie klinischen, radiografischen, echokardiografischen und labordiagnostischen Variablen bei Hunden mit myxomatöser Mitralklappenerkrankung, die mit Pimobendan oder Benazepril behandelt werden: Die QUEST-Studie

  • Jens Haggstrom
  • , Adrian Boswood
  • , Michael O'Grady
  • , Olaf Jons
  • , Sarah Smith
  • , Michele Borgarelli
  • , Brad Gavaghan
  • , Jan-Gerd Kresken
  • , Mark Patteson
  • , Bjorn Ablad
  • , Claudio M. Bussadori
  • , Tony Glaus
  • , Alan Kovacevic
  • , Martin Rapp
  • , Roberto A. Santilli
  • , Anna Tidholm
  • , Anders Eriksson
  • , Marie Claude Belanger
  • , Michael Deinert
  • , Chris J. L. Little
  • Clarence Kvart, Anne French, Mette Ronn-Landbo, Gerhard Wess, Anna Eggertsdottir, M. Lynne O'Sullivan, Matthias Schneider, Christophe W. Lombard, Joe Dukes-McEwan, Ruth Willis, Alexandre Louvet, Rocky DiFruscia

    Publikation: Bidrag till tidskrift › Artikel i vetenskaplig tidskrift › Peer review

    Sammanfattning

    Background: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogsObjectives: To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD.Animals: A total of 260 dogs in CHF because of MMVD.Methods A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day) Differences in outcome variables and time to intensification of CHF treatment were compared.Results: A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = 0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030) Incidence of arrhythmias was similar in treatment groups.Conclusions and clinical importance: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.
    OriginalspråkTyska
    Sidor (från-till)117-134
    TidskriftKleintier-praxis
    Volym59
    Nummer3
    DOI
    StatusPublicerad - 2014

    Nyckelord

    • canine
    • mitral regurgitation
    • mortality
    • therapy

    Citera det här